Details of Disease

Disease Name

Tuberculosis

Disease Class

1B10-1B14: HIV-infected patients with tuberculosis

Disease Hierarchy

DIS01GPL: Grass pollen hypersensitivity

DISZIV9N: Tuberculosis

ICD-11

ICD-11: 1B10-1B1Z

ICD-10

ICD-10: A15-A19, B90

Expand ICD-11

'1B1Z

Expand ICD-10

'A15-A19; 'B90

Expand ICD-9

1.00E+25

Disease Identifiers

MONDO ID

MONDO_0018076

MESH ID

D014376

UMLS CUI

C0041296

MedGen ID

22513

Orphanet ID

3389

SNOMED CT ID

371569005

General Information of Disease (ID: DISZIV9N)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 8 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amikacin	DM5PDRB	Approved	Small molecular drug	[1]
Capreomycin Sulfate	DM346QI	Approved	NA	[2]
Ethionamide	DM8K3EI	Approved	Small molecular drug	[2]
Isoniazid	DM5JVS3	Approved	Small molecular drug	[3]
Prothionamide	DMX0EZJ	Approved	Small molecular drug	[4]
Quinolones	DM5GVHU	Approved	Small molecular drug	[5]
Rifampin	DMA8J1G	Approved	Small molecular drug	[6]
Rifapentine	DMCHV4I	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AdVac tuberculosis vaccine	DM53ZNB	Phase 2	NA	[7]
ID-93/GLA-SE	DM7XIAJ	Phase 2	NA	[8]
Q203	DMN2XK6	Phase 2	NA	[9]
SQ-109	DMWK9BX	Phase 2	Small molecular drug	[9]
Sutezolid	DM2KQ71	Phase 2	Small molecular drug	[10]
Tuberculosis recombinant subunit vaccine	DMC8O2O	Phase 2	NA	[11]
Tuberculosis recombinant vaccine	DMUZYWY	Phase 2	NA	[11]
Tuberculosis vaccine	DMQ8BA6	Phase 2	NA	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ethylene diamine	DMBULX4	Investigative	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
4	Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.
5	The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64.
6	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
7	Clinical pipeline report, company report or official report of Crucell.
8	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036024)
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	ClinicalTrials.gov (NCT01225640) A Study Of PNU-100480 In Newly Diagnosed, Treatment Sensitive Patients With Pulmonary Tuberculosis To Assess Early Bactericidal Activity (EBA) And Whole Blood Activity (WBA). U.S. National Institutes of Health.
11	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12	Clinical pipeline report, company report or official report of Aerus Global TB Vaccine Foundation.